An NHS trial to cure a deadly brain cancer has shrunk the tumour by half in its first patient.Doctors at University College ...
Johnson & Johnson has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for BALVERSA®â–¼ (erdafitinib) as a monotherapy for the treatment ...